Get 40% Off
👀 👁 🧿 All eyes on Biogen, up +4,56% after posting earnings. Our AI picked it in March 2024.
Which stocks will surge next?
Unlock AI-picked Stocks

Teva Pharma Shares Surge on Proposed Opioid Settlement, Earnings Beat

Published 27/07/2022, 17:18
Updated 27/07/2022, 17:18
© Reuters.

Shares of Teva Pharma (TEVA) jumped over 24% in early Wednesday trading following the announcement of its second-quarter results and an agreement, in principle, on a nationwide opioid settlement.

The company beat earnings and revenue forecasts, posting a profit of $0.68 per share on revenue of $3.79 billion. Analysts expected earnings per share of $0.56 on revenue of $3.78 billion.

However, it is the company's opioid settlement announcement that has caught the attention of analysts.

BofA analyst Jason Gerberry, who has a Neutral rating and a $10 per share price target on the stock, said the deal adds "much-needed certainty."

"The opioid agreement looks positive with the NW-deal costing TEVA $3bn in cash (vs. our presumed $5.4bn), of which $650m has already been paid through prior settlements," said Gerberry. "On tomorrow's call, we will look for additional details regarding extent of current participation rates and financial implications of Allergan (NYSE:AGN) "indemnification obligations." Per the PR, TEVA's deal does not include a settlement with New York state but the parties are in ongoing settlement negotiations and TEVA's payout amount is adjustable depending on plaintiff participation. Even if a few one-off deal are separately required, we believe a deal encompassing 90% of litigants (same as JNJ (NYSE:JNJ)) leaves TEVA with cushion to consummate a full resolution within prior communicated parameters."

Meanwhile, Raymond James analyst Elliot Wilbur, who has a Market Perform rating on Teva, explained that the long-running opioid litigation saga had "relegated shares to the realm of the uninvestable for the better part of three years."

3rd party Ad. Not an offer or recommendation by Investing.com. See disclosure here or remove ads .

"It took longer and was ultimately more costly than expected but outside a few clean-up items, the global settlement appears for all intents and purposes to represent the final chapter of these Opioid wars enabling investors to direct their attention to fundamentals without constantly having to chase down every new opioid litigation headline," added Wilbur.

In its earnings report, Teva said it sees fiscal 2022 earnings per share between $2.40 and $2.60 with revenue between $15 billion and 15.6 billion.

By Sam Boughedda

Latest comments

Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2024 - Fusion Media Limited. All Rights Reserved.